Clinical Trial Update: A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating four doses of AZD3355 to estimate its effect on reflux episodes in patients with Gastroesophageal Reflux Disease; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• AZD3355

Snippet

Sponsor: AstraZeneca | Conditions: Gastroesophageal Reflux Disease | Phase 2 | Status: COMPLETED | Results posted: 2011-06-14